Novo: More type 2 diabetics benefit from early Victoza therapy

09/13/2011 | Reuters

Novo Nordisk said a large number of patients with type 2 diabetes who received early treatment with Victoza met a target level for blood glucose compared with those treated later, according to data presented at a conference of the European Association for the Study of Diabetes. Early use of Victoza also led to greater clinical benefit and improved beta-cell function, the drugmaker reported. Traditionally, metformin is given as first-line therapy for diabetes.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX